COMPANY PROFILE

Seranova Bio

Explore full profile

Seranova: Pioneering the future of therapeutics with cutting-edge innovation

South San Francisco, United StatesFounded 2020Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Seranova Bio

Seranova Bio is a cutting-edge biotechnology startup focused on revolutionizing our understanding of autoantibodies and their role in various diseases. Autoantibodies are antibodies that mistakenly target and react with a person's own tissues or organs. Seranova Bio's mission is to unlock the potential of these naturally occurring autoantibodies to develop new, life-changing treatments for diseases such as cancer, rheumatoid arthritis, and neurodegenerative disorders.

The company operates in the healthcare and biotechnology market, serving clients that include pharmaceutical companies, research institutions, and healthcare providers. Seranova Bio's proprietary REAP (Rapid Epitope Antibody Profiling) technology is at the core of its business model. This technology overcomes previous limitations in studying autoantibodies, enabling the identification of therapeutic antibodies that can mimic the beneficial effects observed in patients who naturally produce these autoantibodies.

Seranova Bio generates revenue through multiple streams. Primarily, it partners with pharmaceutical companies to co-develop new therapies based on its REAP technology. Additionally, it offers its technology as a service to research institutions and healthcare providers, allowing them to better understand the role of autoantibodies in disease progression and treatment outcomes.

By leveraging its innovative technology, Seranova Bio aims to transform the landscape of therapeutic development, providing new hope for patients with conditions that have been difficult to treat with existing methods.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: South San Francisco, United States
Employees: 13
Open positions: None listed
Dealroom signal: 89.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Feb 2024	$10M	$40M	Undisclosed	↗
OtherOther financing	May 2021	$5M	—	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Seranova Bio website traffic

Latest recorded traffic for Seranova Bio is 3.2K monthly website visits, up 18.5% over the last three months. Seranova Bio's team grew 30% over the past year.

Latest monthly visits3.2K 3-month web change+18.5% 1-year team growth+30%

Monthly website visitsJan 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
3535PharmaAdvancing therapeutic biologics to treat cardiopulmonary and metabolic diseases	Montreal, Canada	Acquired
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
BIBioCaptivaNovel liquid biopsy device for cancer diagnostics	St Andrews, United Kingdom	Operational
MBMICA BiosystemsBiomagnetic technology for remote-controlled regenerative medicine applications	Solihull, United Kingdom	Operational